59. Introduction of a Group A meningococcal conjugate vaccine in the African meningitis belt
Session: Symposium: Vaccines for a Global Community: Meningococcus A and B, Cholera, and Malaria
Thursday, October 20, 2011: 12:30 PM
Room: 205ABC


F. Marc LaForce, MD, FIDSA, Meningitis Vaccine Project, PATH, Ferney-Voltaire, France

F. Marc LaForce, M.D. Director, Meningitis Vaccine Project Dr. LaForce joined the Meningitis Vaccine Project as Director in August 2001. The Meningitis Vaccine Project is a partnership between WHO and PATH aimed at developing, testing, licensing and introducing affordable conjugate meningococcal vaccines in Sub-Saharan Africa. Dr. LaForce earned his Doctor of Medicine degree from Seton Hall College of Medicine and Dentistry in Jersey City, N.J. He completed his internal medicine and infectious disease training on the Harvard Service at Boston City Hospital. After serving as an Epidemic Intelligence Service Officer in the Meningitis and Special Pathogen units at the Centers for Disease Control and Prevention he held academic and research positions at the University of Colorado and the University of Rochester Schools of Medicine. He is board certified in internal medicine and infectious diseases and is a Fellow of the American College of Physicians and the Infectious Diseases Society of America. Contact information PATH, Meningitis Vaccine Project 455 Massachusetts Avenue NW Suite 1000 Washington, DC, 20001 Email fmlaforce@path.org



Previous Presentation | Next Presentation >>

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.